Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Health Catalyst (HCAT) EBITDA Margin (2018 - 2025)

Health Catalyst (HCAT) has disclosed EBITDA Margin for 8 consecutive years, with 17.96% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin fell 410.0% year-over-year to 17.96%, compared with a TTM value of 24.67% through Sep 2025, down 67.0%, and an annual FY2024 reading of 18.59%, up 2003.0% over the prior year.
  • EBITDA Margin was 17.96% for Q3 2025 at Health Catalyst, up from 41.49% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 13.87% in Q3 2024 and bottomed at 66.08% in Q4 2021.
  • Average EBITDA Margin over 5 years is 38.03%, with a median of 41.49% recorded in 2025.
  • The sharpest move saw EBITDA Margin surged 3338bps in 2023, then plummeted -2475bps in 2025.
  • Year by year, EBITDA Margin stood at 66.08% in 2021, then increased by 27bps to 48.5% in 2022, then increased by 18bps to 39.54% in 2023, then surged by 55bps to 17.84% in 2024, then fell by -1bps to 17.96% in 2025.
  • Business Quant data shows EBITDA Margin for HCAT at 17.96% in Q3 2025, 41.49% in Q2 2025, and 20.87% in Q1 2025.